Experience with recombinant human c1 esterase inhibitor for hereditary angioedema attacks during pregnancy

Recombinant human C1 esterase inhibitor (rhC1-INH) is indicated in the United States for treating hereditary angioedema (HAE) attacks in adolescents/adults. Data are limited on rhC1-INH treatment in women with HAE who are pregnant.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Bernstein, D. Moldovan, R. Hakl, L. Bellizzi, A. Relan Tags: P156 Source Type: research